Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/25/2025 | $9.00 | Overweight | Piper Sandler |
| 12/18/2024 | $4.00 | Neutral | Goldman |
| 12/17/2024 | $8.00 | Overweight | Cantor Fitzgerald |
| 6/20/2024 | $2.50 | Neutral → Underperform | BofA Securities |
| 1/3/2024 | Buy → Neutral | BofA Securities | |
| 11/20/2023 | Neutral | JP Morgan | |
| 8/1/2023 | Under Perform → Market Perform | Northland Capital | |
| 6/15/2023 | $1.25 → $4.00 | Underperform → Buy | BofA Securities |
8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)
SCHEDULE 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)
ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmac
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. About Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. T
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem's Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pend
Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy
Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy
Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
Piper Sandler initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $9.00
Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00
Cantor Fitzgerald initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $8.00
ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmac
– Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 2040 – – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidemias – – Partner Otsuka Received Regulatory Approval and Favorable Preliminary Pricing to Market NEXLETOL in Japan, Which Will Trigger Significant Milestone Payments Upon Final Pricing Approval – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, M
ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical comp
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise
ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson's appointment, Esperion's Board of Directors now comprises eight members. "We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership and a proven track record advancing innovative therapies, Craig brings a wealth of strategic insight and operational expertise that will be invaluable as we continue to expand our impact in cardiovascular and cardiometabolic drug devel
– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive